A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12532
Last updated 2026-05-08
Summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Conditions
- Ischemic Stroke; Ischemic Attack, Transient
Interventions
- DRUG
-
Milvexian
Milvexian will be administered orally.
- DRUG
-
Placebo will be administered orally
Sponsors & Collaborators
-
Bristol Myers Squibb Company (BMS)
collaborator UNKNOWN -
Janssen Research & Development, LLC
lead INDUSTRY
Principal Investigators
-
Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-15
- Primary Completion
- 2026-11-11
- Completion
- 2026-12-09
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Croatia
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hong Kong
- Hungary
- India
- Israel
- Italy
- Japan
- Latvia
- Lithuania
- Malaysia
- Mexico
- Netherlands
- New Zealand
- Philippines
- Poland
- Portugal
- Romania
- Serbia
- Singapore
- Slovakia
- South Africa
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Thailand
- Turkey (Türkiye)
- United Kingdom
- Vietnam
Study Locations
More Related Trials
-
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
NCT03766581 ·Status: COMPLETED ·Phase: PHASE2
-
Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes
NCT07121569 ·Status: COMPLETED ·Phase: PHASE4
-
Repinotan in Patients With Acute Ischemic Stroke
NCT00044915 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00061022 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
NCT00401310 ·Status: TERMINATED ·Phase: PHASE2
-
RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke
NCT02129920 ·Status: UNKNOWN
-
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
NCT02928393 ·Status: TERMINATED ·Phase: PHASE2
-
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
NCT01208233 ·Status: TERMINATED ·Phase: PHASE2
-
Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT
NCT05124353 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables
NCT00698763 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
NCT00272909 ·Status: TERMINATED ·Phase: PHASE2
-
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
NCT00821821 ·Status: COMPLETED ·Phase: PHASE2
-
Lixiana Acute Stroke Evaluation Registry
NCT03494530 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
NCT02671461 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
NCT05764122 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
NCT05745311 ·Status: UNKNOWN ·Phase: PHASE2
-
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
NCT00868283 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
NCT01955707 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00119626 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
NCT02730455 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Finding Study of MCI-186 in Acute Ischemic Stroke
NCT03346538 ·Status: TERMINATED ·Phase: PHASE2
-
MLC1501 Study Assessing Efficacy in STROke Recovery
NCT05046106 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
NCT06238024 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
AXIS 2: AX200 for the Treatment of Ischemic Stroke
NCT00927836 ·Status: COMPLETED ·Phase: PHASE2